NuVasive, Inc. NUVA recently announced that it launched the Pulse integrated technology platform. This is a crucial step in the company's endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.
More About the Pulse Platform
Pulse is the first, single platform to comprise multiple technologies developed to help surgeons adopt more efficient, less disruptive surgical approaches in all spine procedures. Designed to improve workflow, lessen variability and improve surgical reproducibility, Pulse meets a wider range of clinical challenges in the operating room in comparison with any other enabling technology in the spine market.
The platform is equipped with several enabling technologies, which allow surgeons and hospitals the flexibility to cater to their patients' needs in all spinal cases. Some of these unique features are 2D and 3D imaging and navigation, surgical planning with Integrated Global Alignment, neuromonitoring, smart imaging with radiation reduction through LessRay, and rod bending with Bendini.
NuVasive completed the limited clinical release testing of the Pulse platform, offering preliminary verification of the fact that its structural design enables broad clinical utility throughout the entire surgery. The platform is useful in all types of spine surgeries, starting from fusions to complicated corrections.
Per Market Research Future , the global market for spinal implants is expected to witness a CAGR of approximately 5.5% during 2017-2023. Hence the launch of this platform is well-timed.
Lately, NuVasive has been investing in several developments, which are expected to strengthen its portfolio of spinal surgery.
In the las t report ed quarter, the Advanced Materials Science (AMS) portfolio, with COHERE, cervical and TLIF Porous PEEK antibodies, has registered nearly 70% year-over-year growth.
In June 2019, NuVasive announced the commercial launch of Modulus TLIF-O, a porous titanium spine implant that is engineered for the transforaminal lumbar interbody fusion (TLIF) procedure.
In April 2019, the company announced that it is set to launch the X360 system, integrated with Pulse for lateral single-position surgery. During the same time, NuVasive announced the first-case uses of Cohere XLIF, a unique lateral Porous PEEK implant for XLIF and lateral single-position surgery. The incorporation of the Porous PEEK technology into lateral single-position surgery is also expected to boost the AMS portfolio of the company.
In the past six months, the stock has gained 26.4% in comparison to the industry 's 17.6% rise.
Zacks Rank and Other Key Picks
NuVasive currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are Teleflex Inc. TFX , Penumbra PEN and Bruker Corporation BRKR . While Penumbra currently sports a Zacks Rank #1, the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Teleflex's long-term earnings growth rate is expected to be 13.7%.
Penumbra's long-term earnings growth rate is projected at 21.5%.
Bruker's long-term earnings growth rate is pegged at 12.6%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teleflex Incorporated (TFX): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research